Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F van Leth

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Epidemiology and Infection|September 2, 2011
Prevalence of smear-positive tuberculosis in persons aged ≥ 15 years in Bangladesh: results from a national survey, 2007-2009K Zaman, S Hossain, S Banu, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
The Journal of Infectious Diseases|March 5, 2004
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?E Fontas, F van Leth, C A Sabin, et al.
AIDS Research and Human Retroviruses|March 21, 2006
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacyF Van Leth, B S Kappelhoff, D Johnson, et al.
The Lancet. Infectious Diseases|January 19, 2008
Measuring tuberculosis burden, trends, and the impact of control programmesC Dye, A Bassili, A L Bierrenbach, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 21, 2008
Tuberculosis prevalence surveys: rationale and costP Glaziou, M J van der Werf, I Onozaki, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 19, 2019
Management of patients with multidrug-resistant tuberculosisC Lange, R E Aarnoutse, J W C Alffenaar, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Epidemiology and Infection|September 2, 2011
Prevalence of smear-positive tuberculosis in persons aged ≥ 15 years in Bangladesh: results from a national survey, 2007-2009K Zaman, S Hossain, S Banu, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
The Journal of Infectious Diseases|March 5, 2004
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?E Fontas, F van Leth, C A Sabin, et al.
AIDS Research and Human Retroviruses|March 21, 2006
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacyF Van Leth, B S Kappelhoff, D Johnson, et al.
The Lancet. Infectious Diseases|January 19, 2008
Measuring tuberculosis burden, trends, and the impact of control programmesC Dye, A Bassili, A L Bierrenbach, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 21, 2008
Tuberculosis prevalence surveys: rationale and costP Glaziou, M J van der Werf, I Onozaki, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 19, 2019
Management of patients with multidrug-resistant tuberculosisC Lange, R E Aarnoutse, J W C Alffenaar, et al.
Pageof 4